KDRA calls for various supportive measures for the timely development of new drugs

Published: 2002-04-26 06:58:00

Updated: 2002-04-26 06:58:00

In the midst of the growing criticism from the domestic pharmaceutical industry over the government policy to discourage the prescription of high-priced drugs through incentive system, the Korea Drug Research Association (KDRA) has asserted that the introduction of incentive system is likely to c...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK